An interventional study of HEARTS implementation support and Routine HEARTS implementation in Hypertension (HTN) and Type 2 Diabetes, sponsored by University of Michigan. Not yet recruiting at 1 site in Guatemala. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Michigan · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Hypertension by University of Michigan — 1 open to participants now, 1 under way, none of them phase 3. Hypertension · University of Michigan.
Among the 28 studies in Hypertension by University of Michigan, this one has the largest planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2027, is one of 22 with no phase, and was the 28th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →1 of the 28 studies in Hypertension by University of Michigan is open now, in 1 country.
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,440 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 94 across the 26 interventional studies, 1,031 across the 2 observational. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Michigan is the lead sponsor of 1,509 studies on the registry; 194 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 134 (79%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Hypertension by University of Michigan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out whether extra support for a program called HEARTS can improve care for people who have both high blood pressure and diabetes. HEARTS was created by the World Health Organization to help primary care health centers deliver better treatment. It is the official model for high blood pressure and diabetes care in Guatemala's Ministry of Health. In this study, 36 Ministry of Health health centers in Guatemala will be randomly assigned to 1 of 2 groups. Health centers in both groups will use HEARTS through the Ministry of Health's routine training, treatment guides, and digital tools. Health centers in 1 group will also receive 36 months of extra support from the Institute of Nutrition of Central America and Panama (INCAP). This support includes refresher training for health workers every 6 months, monthly supportive supervision visits, and coaching of a health center quality committee to use data to improve care. About 1,440 adults who have both high blood pressure and diabetes will take part. Participants will be assessed at the start of the study, at 6 months, and at 12 months. The main measure is systolic blood pressure at 12 months. The most important other measure is hemoglobin A1c (a blood test that shows average blood sugar levels over the past 2 to 3 months) at 12 months.
MULTI-HEARTS is a cluster-randomized, hybrid type 2 effectiveness-implementation trial of implementation support for HEARTS, the official model for hypertension and diabetes primary care in Guatemala's Ministry of Health. Health centers in both arms will implement HEARTS through the Ministry of Health's routine strategies. In the implementation support arm, health centers also will receive additional implementation support strategies directed at health workers, managers, and support staff.
The primary objective is to evaluate whether HEARTS implementation support leads to better hypertension and diabetes control than routine HEARTS implementation among adults with hypertension and diabetes. We hypothesize that implementation support will lead to lower mean systolic blood pressure at 12 months (primary outcome) compared to routine HEARTS implementation. The key secondary outcome is mean hemoglobin A1c (HbA1c) at 12 months. Other secondary outcomes are mean diastolic blood pressure and the proportions of participants with blood pressure control, HbA1c control, and combined blood pressure and HbA1c control at 12 months. The primary implementation outcome is Reach, which is defined in the study to be the monthly number of patients treated with both antihypertensive and glucose-lowering medications at participating health centers. In an economic evaluation, we will also estimate costs, cost-effectiveness, and budget impact.
We will randomize 36 Ministry of Health health centers in a 1:1 ratio, with stratification by health area. We will enroll 1,440 adults aged 18 years or older with systolic blood pressure ≥130 mmHg and HbA1c ≥6.5%. There will be approximately 40 participants per health center and a total of 720 per arm. Allowing for 15% attrition, the trial will have at least 80% power to detect a between-arm difference of 5.0 mmHg in mean systolic blood pressure at 12 months. The health centers serve urban and rural communities, and many participants will live in poverty and have limited literacy. Some trial participants are expected to be Indigenous Maya and will primarily speak a Mayan language rather than Spanish.
After a 1-year trial planning period, health centers will be randomized before the start of the 36-month implementation period. Each participant will be followed for 12 months. Ministry of Health administrative data will also be collected for a 6-month post-trial period. In addition to the trial data, the study includes additional data collection for implementation and economic evaluations.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Routine HEARTS implementation with additional implementation support from INCAP for 36 months.
Other: HEARTS implementation support · Other: Routine HEARTS implementation
Routine HEARTS implementation alone.
Other: Routine HEARTS implementation
Group refresher training every 6 months, monthly supportive supervision visits, and data-driven coaching of a health center quality committee, delivered by INCAP implementation support physicians to health workers, managers, and support staff.
An initial training-of-trainers workshop, Clinical Pathways for hypertension and type 2 diabetes, and digital tools, delivered by the Ministry of Health under its National Strategy for Cardio-Reno-Metabolic Risk Management based on HEARTS.
Systolic blood pressure
Between-arm mean difference in systolic blood pressure, using the mean of 3 automated readings.
Time frame: 12 months after the enrollment visit
Hemoglobin A1c
Key secondary outcome. Between-arm mean difference in hemoglobin A1c, measured with a point-of-care device.
Time frame: 12 months after the enrollment visit
Diastolic blood pressure
Between-arm mean difference in diastolic blood pressure, using the mean of 3 automated readings.
Time frame: 12 months after the enrollment visit
Proportion of participants with blood pressure control
Between-arm difference in the proportion of participants with blood pressure control of \<130/\<80 mmHg, as defined in national guidelines.
Time frame: 12 months after the enrollment visit
Proportion of participants with hemoglobin A1c control
Between-arm difference in the proportion of participants with hemoglobin A1c control of \<7.0%, as defined in national guidelines.
Time frame: 12 months after the enrollment visit
Proportion of participants with combined blood pressure control and hemoglobin A1c control
Between-arm difference in the proportion of participants with combined blood pressure control (\<130/\<80 mmHg) and hemoglobin A1c control (\<7.0%), as defined in national guidelines.
Time frame: 12 months after the enrollment visit
Plan to share: Yes — We will deposit de-identified participant-level data collected at study visits in a data repository selected in accordance with NHLBI policy.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: No later than the time of an associated publication or the end of the performance period, whichever comes first.
Access criteria: The repository will control access to the data in accordance with NHLBI policy.
No publications or documents are linked to this record.
Start is estimated for Oct 2027; primary completion for Sep 2030, 35 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 35 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start May 2027 → Oct 2027, primary completion May 2030 → Sep 2030 and completion May 2030 → Sep 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.